Consecutively hospitalized patients with confirmed coronavirus disease 2019(COVID-19)in Wuhan,China were retrospectively enrolled from January 2020 to March 2020 to investigate the association between the use of renin-angiotensin system inhibitor(RAS-I)and the outcome of this disease.Associations between the use of RAS-I(angiotensin-converting enzyme inhibitor(ACEI)or angiotensin receptor blocker(ARB)),ACEI,and ARB and in-hospital mortality were analyzed using multivariate Cox proportional hazards regression models in overall and subgroup of hypertension status.A total of 2771 patients with COVID-19 were included,with moderate and severe cases accounting for 45.0％and 36.5％,respectively.A total of 195(7.0％)patients died.RAS-I(hazard ratio(HR)=0.499,95％confidence interval(CI)0.325-0.767)and ARB(HR=0.410,95％CI 0.240-0.700)use was associated with a reduced risk of all-cause mortality among patients with COVID-19.For patients with hypertension,RAS-I and ARB applications were also associated with a reduced risk of mortality with HR of 0.352(95％CI 0.162-0.764)and 0.279(95％CI 0.115-0.677),respectively.RAS-I exhibited protective effects on the survival outcome of COVID-19.ARB use was associated with a reduced risk of all-cause mortality among patients with COVID-19.

Huai-yu Wang;Suyuan Peng;Zhanghui Ye;Pengfei Li;Qing Li;Xuanyu Shi;Rui Zeng;Ying Yao;Fan He;Junhua Li;Liu Liu;Shuwang Ge;Xianjun Ke;Zhibin Zhou;Gang Xu;Ming-hui Zhao;Haibo Wang;Luxia Zhang;Erdan Dong

National Institute of Health Data Science at Peking University,Beijing 100191,China;Peking University Advanced Institute of Information Technology,Hangzhou 311215,China;Department of Nephrology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Department of Clinical Nutrition,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Taikang Tongji(Wuhan)Hospital,Wuhan 430050,China;Renal Division,Department of Medicine,Peking University First Hospital,Peking University Institute of Nephrology,Beijing 100034,China;Peking-Tsinghua Center for Life Sciences,Beijing 100871,China;First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China;Department of Cardiology and Institute of Vascular Medicine,Peking University Third Hospital;Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides,Ministry of Health;Key Laboratory of Molecular Cardiovascular Sciences,Ministry of Education;Beijing Key Laboratory of Cardiovascular Receptors Research,Beijing 100191,China

医学前沿

[1]Huai-yu Wang;Suyuan Peng;Zhanghui Ye;Pengfei Li;Qing Li;Xuanyu Shi;Rui Zeng;Ying Yao;Fan He;Junhua Li;Liu Liu;Shuwang Ge;Xianjun Ke;Zhibin Zhou;Gang Xu;Ming-hui Zhao;Haibo Wang;Luxia Zhang;Erdan Dong-.Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension)[J].医学前沿,2022(01):102-110

Consecutively

Renin,angiotensin,system,inhibitor,associated,reduced,risk,cause,mortality,among,patients,without,hypertension,hospitalized,confirmed,coronavirus,disease,Wuhan,China,were,retrospectively,enrolled,from,January,March,investigate,association,between,renin,RAS,outcome,this,Associations,converting,enzyme,ACEI,receptor,blocker,ARB,analyzed,using,multivariate,Cox,proportional,hazards,regression,models,overall,subgroup,status,total,included,moderate,severe,cases,accounting,respectively,died,ratio,confidence,interval,was,For,applications,also,exhibited,protective,effects,survival

0.44416